Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Feb 28, 2024
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Protagonist Therapeutics, Inc
| -4.28K |
$29.53 | -$126,447.46 | -2.28% | 183.28K |
Feb 26
| |||||||
Protagonist Therapeutics, Inc
|
0
|
$16.19 | -$88,100.00 |
—
| 187.57K |
Jan 9
|
Scheduled
| ||||||
Protagonist Therapeutics, Inc
| 19.25K |
—
|
—
| +11.44% | 187.57K |
Jan 2
| |||||||
Protagonist Therapeutics, Inc
| 20K |
$7.38 | $147,600.00 | +13.48% | 168.32K |
Oct 19
| |||||||
Protagonist Therapeutics, Inc
| 7.85K |
$26.07 | -$108,190.50 | +5.60% | 148.04K |
May 31
| |||||||
Protagonist Therapeutics, Inc
| 20.63K |
—
|
—
| +17.54% | 138.19K |
Jan 16
| |||||||
Protagonist Therapeutics, Inc
| 40K |
$7.38 | $295,200.00 | +51.57% | 117.56K |
Apr 26
| |||||||
Protagonist Therapeutics, Inc
| -649.00 |
$24.28 | -$15,757.72 | -0.84% | 77.01K |
Feb 28
| |||||||
Protagonist Therapeutics, Inc
| 12.5K |
—
|
—
| +19.18% | 77.66K |
Feb 15
| |||||||
Protagonist Therapeutics, Inc
| 12K |
—
|
—
| +23.08% | 63.99K |
Feb 26
| |||||||
Protagonist Therapeutics, Inc
|
0
|
—
|
—
|
—
|
0
|
Feb 28
| |||||||
Protagonist Therapeutics, Inc
| 30K |
$5.13 | $153,900.00 | +153.85% | 49.5K |
Dec 3
| |||||||
Protagonist Therapeutics, Inc
| 7.5K |
—
|
—
| +75.00% | 17.5K |
Feb 28
| |||||||
Protagonist Therapeutics, Inc
|
0
|
—
|
—
|
—
|
0
|
Jan 15
| |||||||
Protagonist Therapeutics, Inc
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||